Current Status and Future Perspectives of Xenotransplantation and Stem Cell Research in Transplantation Field
Article information
J Korean Med Assoc. 2008;51(8):732-744
Publication date (electronic) : 2008 August 31
doi :
https://doi.org/10.5124/jkma.2008.51.8.732
Abstract
The severe shortage of human organ donors is one of the biggest problems with organ transplantation. The solution for this problem would be development of artificial organs or mechanical devices, stem cell derived organs, and xenogeneic organs. Artificial organs may provide a short term life or functional support, but they cannot be considered as a life-long curative therapeutic modality in the near future. Although considerable efforts have been invested in the production of lab-grown organs using stem cells, clinical application of these organs will demand many years of research and investment. Currently, stem cells are clinically applied in cell replacement therapy. Therefore, xenotransplantation would be the most imminent solution for the organ shortage. Recent advances in our understanding of the mechanisms of xenograft rejection, zoonotic infections including PERV (porcine endogenous retrovirus), and production of α-1,3-galactosyltransferase-deficient pigs, put xenotransplantation closer to the clinical reality. At this stage, pancreatic islet xenotransplantation would be the first target for clinical application, the efficacy of which has been proven in non-human primate study and is waiting for the development of relatively non-toxic or clinically applicable immunosuppressive or tolerance-inducing regimens.
Keywords: Stem cell; Xenotransplantation; Pig; Genetic engineering; Regenerative medicine
Notes
This study was supported by a grant from the National R & D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(A040004).
References
1. Yang YG, Sykes M. Xenotransplantation: current status and a perspective on the future. Nature reviews 2007. 7519–531.
2. Pratschke J, Wilhelm MJ, Kusaka M, Basker M, Cooper DK, Hancock WW, Tilney NL. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999. 67343–348.
3. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 2000. 529–35.
4. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, Dorling A. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001. 1260–269.
5. Cooper DK, Gollackner B, Sachs DH. Will the pig solve the transplantation backlog? Annual review of medicine 2002. 53133–147.
6. Fishman JA. Infection in xenotransplantation. Journal of cardiac surgery 2001. 16363–373.
7. Fishman JA. Infection and xenotransplantation. Developing strategies to minimize risk. Annals of the New York Academy of Sciences 1998. 86252–66.
8. Setcavage TM, Kim YB. Variability of the immunological state of germfree colostrum-deprived Minnesota miniature piglets. Infection and immunity 1976. 13600–607.
9. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. The Journal of experimental medicine 1984. 1601519–1531.
10. Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplantation proceedings 1992. 24559–562.
11. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunology today 1993. 14480–482.
12. Shimizu I, Smith NR, Zhao G, Medof E, Sykes M. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006. 8195–100.
13. Gollackner B, Goh SK, Qawi I, Buhler L, Knosalla C, Daniel S, Kaczmarek E, Awwad M, Cooper DK, Robson SC. Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004. 771735–1741.
14. Ramírez P, Montoya MJ, Ríos A, García Palenciano C, Majado M, Chávez R, Muñoz A, Fernández OM, Sánchez A, Segura B, Sansano T, Acosta F, Robles R, Sánchez F, Fuente T, Cascales P, González F, Ruiz D, Martínez L, Pons JA, Rodríguez JI, Yélamos J, Cowan P, d'Apice A, Parrilla P. Prevention of hyperacute rejection in a model of orthotopic liver xenotransplantation from pig to baboon using polytransgenic pig livers (CD55, CD59, and H-transferase). Transplantation proceedings 2005. 374103–4106.
15. Schulte am Esch J 2nd, Rogiers X, Robson SC. Molecular incompatibilities in hemostasis between swine and men-impact on xenografting. Ann Transplant 2001. 612–16.
16. Lee KF, Salvaris EJ, Roussel JC, Robson SC, d'Apice AJ, Cowan PJ. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008. 15191–197.
17. Davila E, Byrne GW, LaBreche PT, McGregor HC, Schwab AK, Davies WR, Rao VP, Oi K, Tazelaar HD, Logan JS, McGregor CG. T-cell responses during pig-to-primate xenotransplantation. Xenotransplantation 2006. 1331–40.
18. Kuwaki K, Tseng YL, Dor FJ, Shimizu A, Houser SL, Sanderson TM, Lancos CJ, Prabharasuth DD, Cheng J, Moran K, Hisashi Y, Mueller N, Yamada K, Greenstein JL, Hawley RJ, Patience C, Awwad M, Fishman JA, Robson SC, Schuurman HJ, Sachs DH, Cooper DK. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nature medicine 2005. 1129–31.
19. Forte P, Lilienfeld BG, Baumann BC, Seebach JD. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J Immunol 2005. 1755463–5470.
20. Yi S, Hawthorne WJ, Lehnert AM, Ha H, Wong JK, van Rooijen N, Davey K, Patel AT, Walters SN, Chandra A, O'Connell PJ. T cell-activated macrophages are capable of both recognition and rejection of pancreatic islet xenografts. J Immunol 2003. 1702750–2758.
21. Wang H, VerHalen J, Madariaga ML, Xiang S, Wang S, Lan P, Oldenborg PA, Sykes M, Yang YG. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 2007. 109836–842.
22. Taniguchi S, Neethling FA, Korchagina EY, Bovin N, Ye Y, Kobayashi T, Niekrasz M, Li S, Koren E, Oriol R, Cooper DK. In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal (alpha)1-3Gal column. Transplantation 1996. 621379–1384.
23. Ye Y, Neethling FA, Niekrasz M, Koren E, Richards SV, Martin M, Kosanke S, Oriol R, Cooper DK. Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts. Transplantation 1994. 58330–337.
24. Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 2001. 8157–171.
25. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM 3rd, Matas AJ. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993. 55857–865.
discussion 65-66.
26. Kang HJ, Lee G, Kim JY, Lee SH, Wi HC, Hwang PG, Chung DH, Kim YT. Pre-treatment of donor with 1-deamino-8-darginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient. Eur J Cardiothorac Surg 2005. 28149–156.
27. Lambrigts D, Sachs DH, Cooper DK. Discordant organ xenotransplantation in primates: world experience and current status. Transplantation 1998. 66547–561.
28. Cowan PJ, Aminian A, Barlow H, Brown AA, Dwyer K, Filshie RJ, Fisicaro N, Francis DM, Gock H, Goodman DJ, Katsoulis J, Robson SC, Salvaris E, Shinkel TA, Stewart AB, d'Apice AJ. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002. 2520–525.
29. Byrne GW, Schirmer JM, Fass DN, Teotia SS, Kremers WK, Xu H, Naziruddin B, Tazelaar HD, Logan JS, McGregor CG. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005. 51011–1020.
30. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, Fisicaro N, Mysore TB, Kaczmarek E, Cowan PJ, d'Apice AJ. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. The Journal of clinical investigation 2004. 1131440–1446.
31. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, Samuel M, Bonk A, Rieke A, Day BN, Murphy CN, Carter DB, Hawley RJ, Prather RS. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002. 2951089–1092.
32. Yamada K, Yazawa K, Shimizu A, Iwanaga T, Hisashi Y, Nuhn M, O'Malley P, Nobori S, Vagefi PA, Patience C, Fishman J, Cooper DK, Hawley RJ, Greenstein J, Schuurman HJ, Awwad M, Sykes M, Sachs DH. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nature medicine 2005. 1132–34.
33. Crikis S, Cowan PJ, d'Apice AJ. Intravascular thrombosis in discordant xenotransplantation. Transplantation 2006. 821119–1123.
34. Groth CG, Korsgren O, Tibell A, Tollemar J, Möller E, Bolinder J, Ostman J, Reinholt FP, Hellerström C, Andersson A, Simeonovic CJ. Xenogeneic islet transplantation. Xenotransplantation 1999. 61–5.
35. Rood PP, Buhler LH, Bottino R, Trucco M, Cooper DK. Pig-to-nonhuman primate islet xenotransplantation: a review of current problems. Cell transplantation 2006. 1589–104.
36. Groth CG, Korsgren O, Tibell A, Tollemar J, Möller E, Bolinder J, Ostman J, Reinholt FP, Hellerström C, Andersson A. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994. 3441402–1404.
37. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Upsala journal of medical sciences 2000. 105125–133.
38. Bennet W, Sundberg B, Lundgren T, Tibell A, Groth CG, Richards A, White DJ, Elgue G, Larsson R, Nilsson B, Korsgren O. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 2000. 69711–719.
39. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004. 77741–747.
40. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, Bello-Laborn H, Hacquoil B, Strobert E, Gangappa S, Weber CJ, Pearson TC, Rajotte RV, Larsen CP. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nature medicine 2006. 12304–306.
41. Hering BJ, Wijkstrom M, Graham ML, Hårdstedt M, Aasheim TC, Jie T, Ansite JD, Nakano M, Cheng J, Li W, Moran K, Christians U, Finnegan C, Mills CD, Sutherland DE, Bansal-Pakala P, Murtaugh MP, Kirchhof N, Schuurman HJ. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nature medicine 2006. 12301–303.
42. Kim JH, Kim HI, Lee KW, Yu JE, Kim SH, Park HS, Park CG, Ihm SH, Ha J, Kim SJ, Lee HK, Ahn C, Park KS. Influence of strain and age differences on the yields of porcine islet isolation: extremely high islet yields from SPF CMS miniature pigs. Xenotransplantation 2007. 1460–66.
43. Fishman JA, Patience C. Xenotransplantation: infectious risk revisited. Am J Transplant 2004. 41383–1390.
44. Garkavenko O, Muzina M, Muzina Z, Powels K, Elliott RB, Croxson MC. Monitoring for potentially xenozoonotic viruses in New Zealand pigs. Journal of medical virology 2004. 72338–344.
45. Rowinski W. Future of transplantation medicine. Ann Transplant 2007. 125–10.
46. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, Taylor DA. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nature medicine 2008. 14213–221.
47. Biotech Policy Research Center. Report for patent map. Trend in industry 2007. 45.
48. Yamanaka S. Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci 2008. 3632079–2087.
49. Rowinski W. Future of transplantation medicine. Ann Transplant 2007. 125–10.
50. Mimeault Murielle, Batra Surinder. K.. Recent Progress on Tissue-Resident Adult Stem Cell Biology and Their Therapeutic Implications. Stem Cell Rev 2008. 427–49.
51. Bryder D, Rossi DJ, Weissman IL. Hemato-poietic stem cells: the paradigmatic tissue-specific stem cell. American Journal of Pathology 2006. 169338–346.
52. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007. 25818–827.
53. Dhawan J, Rando TA. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quie-scence, activation and replenishment. Trends in Cell Biology 2005. 15666–673.
54. Watts C, McConkey H, Anderson L, Caldwell M. Anatomical perspectives on adult neural stem cells. Journal of Anatomy 2005. 207197–208.
55. Lim DA, Huang YC, Alvarez-Buylla A. The adult neural stem cell niche: lessons for future neural cell replacement strategies. Neurosurgery Clinics of North America 2007. 1881–92.
56. Koblas T, Zacharovová K, Berková Z, Mindlová M, Girman P, Dovolilová E, Karasová L, Saudek F. Isolation and characterization of human CXCR4- positive pancreatic cells. Folia Biologica (Praha) 2007. 5313–22.
57. Bonner-Weir S, Weir GC. New sources of pan-creatic beta-cells. Nature Biotechnology 2005. 23857–861.
58. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted gene delivery vehicles. Handb Exp Pharmacol 2007. 180263–283.
59. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006. 30353–361.
60. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow derived mesenchymal stem cells as vehicles for interferon-b delivery into tumors. Cancer Res 2002. 623603–3608.
61. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006. 811390–1397.
62. Choi SC, Kim GH, Lee SJ, Park E, Yeo CY, Han JK. Regulation of activin/nodal signaling by Rap2-directed receptor trafficking. Dev Cell 2008. 1549–61.
63. Yang YJ, Lee HJ, Choi DH, Huang HS, Lim SC, Lee MK. Effect of scoparone on neurite outgrowth in PC12 cells. Neurosci Lett 2008. 44014–18.
Epub 2008 May 18.
64. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008. 2241–251.
65. Sykes M, d'Apice A, Sandrin M. Position paper of the Ethics Committee of the International Xenotransplantation Association. Xenotransplantation 2003. 10194–203.
66. Sykes M. Commentary: World Health Assembly resolution 57.18 on xenotransplantation. Transplantation 2005. 79636–637.
Article information Continued
Copyright © 2008 Korean Medical Association
